http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 10 Jul 2026 06:45:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/Opus+Genetics+%28IRD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+on+Positive+Update/26755010.html <p>Cantor Fitzgerald analyst Steve Seedhouse reiterated an Overweight rating and $15.00 price target on Opus Genetics (NASDAQ: IRD).</p><p>The analyst commented, "Opus provided a fairly comprehensive (and in our view, positive) logistical update for its ongoing Phase 1/2 BIRD-1 trial testing BEST1 gene therapy OPGx-BEST1 that could be generally interpreted in our view as saying "expect dose escalation at some point because it is the prudent thing to do, but don't read anything negative into it". BEST1 disease affects potentially >8,000 people in the U.S. alone, has no available treatment options, and Opus already presented compelling initial data (BCVA and CST http://www.streetinsider.com/Analyst+Comments/Opus+Genetics+%28IRD%29+Reiterated+at+Overweight+by+Cantor+Fitzgerald+on+Positive+Update/26755010.html Fri, 10 Jul 2026 06:45:51 -0400 IRD http://www.streetinsider.com/Corporate+News/Opus+Genetics+sets+September+timeline+for+OPGx-BEST1+trial+data/26749970.html <p>Opus Genetics, Inc. (Nasdaq: IRD) said it expects to announce three-month topline data from Cohort 1 of its Phase 1/2 OPGx-BEST1 clinical trial during the second week of September 2026, contingent on all participants completing their scheduled assessments.</p><p>The company also plans to present the data at the EURETINA Congress in Vienna, Austria, scheduled for October 1-4, 2026.</p><p>The trial, called BIRD-1, is an adaptive, open-label study evaluating the safety and efficacy of OPGx-BEST1, a gene therapy candidate for Best Vitelliform Macular Dystrophy (BVMD) and Autosomal-Recessive Bestrophinopathy (ARB). Enrollment in Cohort 1 was completed in May 2026 with five participants — three http://www.streetinsider.com/Corporate+News/Opus+Genetics+sets+September+timeline+for+OPGx-BEST1+trial+data/26749970.html Thu, 09 Jul 2026 07:02:16 -0400 IRD http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Press+Releases/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html <p>RESEARCH TRIANGLE PARK, N.C., July 09, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gS_-jJowCsFrszT351mc0HdFkfwZtJQq4NaFaPl1WZyvdTTgYsWodPwopagI2Kh76_tMX-xNgPa916J9baEm_8DESXlX4l4qxoFor6bukmiEIcd0GjZSPpdK23pYCv8jI5lChu7BTXIaoOUcWMiBvQy_QTTsLO4Wb-Kcbc-_cr9KnWc8_ZcCuPbWqnNMTWaqWOu22wBDIuOQva3P61urq2IgsyV2yYjUGO1_FKoVhqpbah6VF5Jf4A5MM_SYvVdEPOal8vnM7_loGs5MivUNgLF7EUKDECcoUdAwVcAY3iYA_qHRW6p6OeP78YYXU4UFRL0x7ZSAOwzKnPpg6eVXCJDgbcs33_47y8OgMOAOj6vULvUJ3oDV_CM0CS9dSw7eu0rGxW1KQ0hqsqeEkslQ0gyIQBHlQqlWM9uz-fZZl6QaJImdcXD_B51FofVAuluv" rel="nofollow" target="_blank">Opus Genetics, Inc.</a> (Nasdaq: IRD) (the “Company”, “Opus Genetics” or “Opus”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today provided updates on its ongoing OPGx-BEST1 Phase 1/2 clinical trial (BIRD-1) targeting BEST-1 associated IRDs.</p> <p>Opus expects to announce three-month topline data from Cohort 1 of the Phase 1/2 trial during the second week of September 2026, assuming all participants complete their assessments as scheduled. In addition, the Company plans to present http://www.streetinsider.com/Globe+Newswire/Opus+Genetics+Provides+BEST1+Program+Update+with+Detailed+Timeline+for+OPGx-BEST1+Results/26749896.html Thu, 09 Jul 2026 07:00:00 -0400 A.06822034 A.60012014 IRD O.01227350 O.20026344 O.20032830 http://www.streetinsider.com/Analyst+Comments/BTIG+on+Opus+Genetics+%28IRD%29%3A+%27the+path+from+here+to+BLA+submission+seems+clear%27/26734367.html <p>BTIG analyst Thomas Shrader reiterated a Buy rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).</p><p>The analyst comments "Another turn of the crank in Opus' relentless drive to get a half dozen gene replacement therapies approved for IRDs (Exhibit 1 is the named pipeline, but there are several more floating around the academic world Opus may grab as cash allows). Each story is backed by a predictive animal model and the constructs are already built with regulatory elements either used in approved LUXTURNA (safe, life changing and stable for a decade and counting) or closely related. The only stretch http://www.streetinsider.com/Analyst+Comments/BTIG+on+Opus+Genetics+%28IRD%29%3A+%27the+path+from+here+to+BLA+submission+seems+clear%27/26734367.html Mon, 06 Jul 2026 12:06:22 -0400 IRD http://www.streetinsider.com/Analyst+Comments/B.Riley+on+Opus+Genetics+%28IRD%29%3A+%27we+remain+buyers%27/26734364.html <p>B.Riley analyst Mayank Mamtani reiterated a Buy rating and $10.00 price target on Opus Genetics (NASDAQ: IRD).</p><p>The analyst comments "Following an update from Opus Genetics (IRD — Buy. $10 PT) on 7/6, BMO, we remain buyers into a catalyst-rich 2H, with shares up ~2x YTD but still 27% off their YTD high. Most importantly, IRD reported FDA alignment on the registrational Phase 3 design for OPGx-LCA5 (LCA5-associated inherited retinal disease), which we believe pulls the estimated BLA submission forward by ~two quarters, to 3Q27 from 1Q28. We view the update as unambiguously de-risking, as it also locks a clean singlearm http://www.streetinsider.com/Analyst+Comments/B.Riley+on+Opus+Genetics+%28IRD%29%3A+%27we+remain+buyers%27/26734364.html Mon, 06 Jul 2026 12:05:26 -0400 IRD http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html <p>Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design of a Phase 3 registrational clinical trial for OPGx-LCA5, a gene therapy candidate targeting LCA5-associated inherited retinal disease.</p> <p>The company said it received meeting minutes from a Type B Rare Disease Evidence Principles meeting confirming key elements of the trial design. The Phase 3 study is expected to enroll eight participants, each with both eyes treated, and will include a six-month run-in period in which participants serve as their own natural history controls before receiving treatment. Seven of the eight planned http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html Mon, 06 Jul 2026 07:01:07 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html <p>Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design of a Phase 3 registrational clinical trial for OPGx-LCA5, a gene therapy candidate targeting LCA5-associated inherited retinal disease.</p> <p>The company said it received meeting minutes from a Type B Rare Disease Evidence Principles meeting confirming key elements of the trial design. The Phase 3 study is expected to enroll eight participants, each with both eyes treated, and will include a six-month run-in period in which participants serve as their own natural history controls before receiving treatment. Seven of the eight planned http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html Mon, 06 Jul 2026 07:01:07 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html <p>Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design of a Phase 3 registrational clinical trial for OPGx-LCA5, a gene therapy candidate targeting LCA5-associated inherited retinal disease.</p> <p>The company said it received meeting minutes from a Type B Rare Disease Evidence Principles meeting confirming key elements of the trial design. The Phase 3 study is expected to enroll eight participants, each with both eyes treated, and will include a six-month run-in period in which participants serve as their own natural history controls before receiving treatment. Seven of the eight planned http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html Mon, 06 Jul 2026 07:01:07 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html <p>Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design of a Phase 3 registrational clinical trial for OPGx-LCA5, a gene therapy candidate targeting LCA5-associated inherited retinal disease.</p> <p>The company said it received meeting minutes from a Type B Rare Disease Evidence Principles meeting confirming key elements of the trial design. The Phase 3 study is expected to enroll eight participants, each with both eyes treated, and will include a six-month run-in period in which participants serve as their own natural history controls before receiving treatment. Seven of the eight planned http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html Mon, 06 Jul 2026 07:01:07 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html <p>Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design of a Phase 3 registrational clinical trial for OPGx-LCA5, a gene therapy candidate targeting LCA5-associated inherited retinal disease.</p> <p>The company said it received meeting minutes from a Type B Rare Disease Evidence Principles meeting confirming key elements of the trial design. The Phase 3 study is expected to enroll eight participants, each with both eyes treated, and will include a six-month run-in period in which participants serve as their own natural history controls before receiving treatment. Seven of the eight planned http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html Mon, 06 Jul 2026 07:01:07 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html <p>Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design of a Phase 3 registrational clinical trial for OPGx-LCA5, a gene therapy candidate targeting LCA5-associated inherited retinal disease.</p> <p>The company said it received meeting minutes from a Type B Rare Disease Evidence Principles meeting confirming key elements of the trial design. The Phase 3 study is expected to enroll eight participants, each with both eyes treated, and will include a six-month run-in period in which participants serve as their own natural history controls before receiving treatment. Seven of the eight planned http://www.streetinsider.com/FDA/Opus+Genetics+gets+FDA+alignment+on+Phase+3+eye+gene+therapy+trial/26732564.html Mon, 06 Jul 2026 07:01:07 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+FDA+Alignment+on+Phase+3+Registrational+Trial+Design+for+OPGx-LCA5+in+LCA5-Associated+Inherited+Retinal+Disease/26732547.html <p align="center"><em>Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design<br/></em><em>FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review<br/></em><em>Company expects to initiate Phase 3 dosing in 4Q 2026</em></p> <p>RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jz1O2mc0JgYR0P5NcypFttjm5-aSOF6hpMuzb7Et-iH02d-zyQ3hJbDXAAmayW6Kx_MbFt0FiH1SI97LVKJImK6boNOa7IRicHQF6dW_TVYWCdKUgXdITDGkqq2gBnjx5PqPsjBEqnz8MVIqYPk_3Ku2nuWSXlpFRzgfPzWcCtQGSi2b5J7hmVI9IzxD_o6cvnBDKvS71P-RfWLfkunjRNwvv7ufdgDq5z8-r3Rcc2B9FjqXt7ef8VVHHf5l2C12-Dw4QbpfpECugmFwnJlqqhC1Fz30jChpIzzNUcIQ3psGQdFyse3qDpj-1C7tWlsyb48DeJD4XohNf1UE13G2r5AlLtBJPbP7gTGToY-nv58w-oTwc9nXgvkSgplkTJSMC9pqp1STU7iXif21eelKpBzhiN2SpU9Q23Uekqd4hhuvLEN_BihbAtLdknNEYbCf" rel="nofollow" target="_blank">Opus Genetics, Inc</a>. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has reached alignment with the U.S. Food http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+FDA+Alignment+on+Phase+3+Registrational+Trial+Design+for+OPGx-LCA5+in+LCA5-Associated+Inherited+Retinal+Disease/26732547.html Mon, 06 Jul 2026 07:00:00 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+FDA+Alignment+on+Phase+3+Registrational+Trial+Design+for+OPGx-LCA5+in+LCA5-Associated+Inherited+Retinal+Disease/26732547.html <p align="center"><em>Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design<br/></em><em>FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review<br/></em><em>Company expects to initiate Phase 3 dosing in 4Q 2026</em></p> <p>RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jz1O2mc0JgYR0P5NcypFttjm5-aSOF6hpMuzb7Et-iH02d-zyQ3hJbDXAAmayW6Kx_MbFt0FiH1SI97LVKJImK6boNOa7IRicHQF6dW_TVYWCdKUgXdITDGkqq2gBnjx5PqPsjBEqnz8MVIqYPk_3Ku2nuWSXlpFRzgfPzWcCtQGSi2b5J7hmVI9IzxD_o6cvnBDKvS71P-RfWLfkunjRNwvv7ufdgDq5z8-r3Rcc2B9FjqXt7ef8VVHHf5l2C12-Dw4QbpfpECugmFwnJlqqhC1Fz30jChpIzzNUcIQ3psGQdFyse3qDpj-1C7tWlsyb48DeJD4XohNf1UE13G2r5AlLtBJPbP7gTGToY-nv58w-oTwc9nXgvkSgplkTJSMC9pqp1STU7iXif21eelKpBzhiN2SpU9Q23Uekqd4hhuvLEN_BihbAtLdknNEYbCf" rel="nofollow" target="_blank">Opus Genetics, Inc</a>. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has reached alignment with the U.S. Food http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+FDA+Alignment+on+Phase+3+Registrational+Trial+Design+for+OPGx-LCA5+in+LCA5-Associated+Inherited+Retinal+Disease/26732547.html Mon, 06 Jul 2026 07:00:00 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506 http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+FDA+Alignment+on+Phase+3+Registrational+Trial+Design+for+OPGx-LCA5+in+LCA5-Associated+Inherited+Retinal+Disease/26732547.html <p align="center"><em>Successful Type B RDEP Meeting confirms FDA alignment on pivotal Phase 3 study design<br/></em><em>FDA indicates Opus Genetics may submit a BLA based on 6-month efficacy data, with 12-month durability data provided during review<br/></em><em>Company expects to initiate Phase 3 dosing in 4Q 2026</em></p> <p>RESEARCH TRIANGLE PARK, N.C., July 06, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=jz1O2mc0JgYR0P5NcypFttjm5-aSOF6hpMuzb7Et-iH02d-zyQ3hJbDXAAmayW6Kx_MbFt0FiH1SI97LVKJImK6boNOa7IRicHQF6dW_TVYWCdKUgXdITDGkqq2gBnjx5PqPsjBEqnz8MVIqYPk_3Ku2nuWSXlpFRzgfPzWcCtQGSi2b5J7hmVI9IzxD_o6cvnBDKvS71P-RfWLfkunjRNwvv7ufdgDq5z8-r3Rcc2B9FjqXt7ef8VVHHf5l2C12-Dw4QbpfpECugmFwnJlqqhC1Fz30jChpIzzNUcIQ3psGQdFyse3qDpj-1C7tWlsyb48DeJD4XohNf1UE13G2r5AlLtBJPbP7gTGToY-nv58w-oTwc9nXgvkSgplkTJSMC9pqp1STU7iXif21eelKpBzhiN2SpU9Q23Uekqd4hhuvLEN_BihbAtLdknNEYbCf" rel="nofollow" target="_blank">Opus Genetics, Inc</a>. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has reached alignment with the U.S. Food http://www.streetinsider.com/Press+Releases/Opus+Genetics+Announces+FDA+Alignment+on+Phase+3+Registrational+Trial+Design+for+OPGx-LCA5+in+LCA5-Associated+Inherited+Retinal+Disease/26732547.html Mon, 06 Jul 2026 07:00:00 -0400 A.03607790 A.06822034 IRD O.01227350 O.20026344 O.20147506